COVID-19: risk for cytokine targeting in chronic inflammatory diseases?

COVID-19, caused by the SARS-CoV-2 virus, has become pandemic. With sharply rising infection rates, patient groups characterized by an enhanced infection risk will be challenged by the virus. In this context, patients with chronic immune-mediated inflammatory diseases are of particular interest, as...

Descripción completa

Detalles Bibliográficos
Autores principales: Schett, Georg, Sticherling, Michael, Neurath, Markus F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Comment
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7186927/
https://www.ncbi.nlm.nih.gov/pubmed/32296135
http://dx.doi.org/10.1038/s41577-020-0312-7
Descripción
Sumario:COVID-19, caused by the SARS-CoV-2 virus, has become pandemic. With sharply rising infection rates, patient groups characterized by an enhanced infection risk will be challenged by the virus. In this context, patients with chronic immune-mediated inflammatory diseases are of particular interest, as these diseases are characterized by an intrinsic immune dysfunction leading to inflammation that may enhance risk for severe infection.

Ejemplares similares